1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional is sponsored by National Human Genome Research Institute (NHGRI). This limited competition NOFO supports transdisciplinary ELSI research addressing timely, complex, and understudied topics associated with advances in human genetics and genomics.
It specifically aims to establish ELSI research teams that include partnerships with relevant communities affected by and with an interest in the proposed research, research capacity building, and workforce development opportunities for early career scholars and research team members.
Eligible applicants are domestic organizations located in the United States and its territories that received less than $30 million per year in total NIH funding for the past three fiscal years, and are underrepresented among those receiving NHGRI funding for ELSI research.
Get alerted about grants like this
Get emailed when new opportunities from “National Human Genome Research Institute (NHGRI)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Domestic organizations located in the United States and its territories that received less than $30 million per year in total NIH funding for the past three fiscal years. Confirm the full requirements in the official notice before applying.
Applications for Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional are due July 31, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional is funded by National Human Genome Research Institute (NHGRI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
This initiative will stimulate and support innovative research by small business concerns that may lead to the development of novel technologies for the early diagnosis, monitoring and treatment of micro and macro vascular complications of diabetes which are associated with significant morbidity and mortality of the disease and high costs to the health care system. Funding Opportunity Number: PA-14-058. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL.
While headlines chase AI and defense money, USDA's National Institute of Food and Agriculture runs a tight summer competitive cycle — Equipment Grants (June 25), Agricultural Genome to Phenome (June 29), New Beginning for Tribal Students (July 2), and Crop Protection and Pest Management (July 6). Here is how the four programs fit together, who is eligible, and why the land-grant system has a structural edge.
Read articleThe STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read articleThe Complement-ARIE program funds seven technology centers to develop human-based models that complement animal research. What it means for drug developers, academic researchers, and the regulatory pipeline.
Read article